CellProthera Partners with Quintessence Biotech to Advance Cell Therapy Manufacturing

CellProthera announces a new collaboration to optimize manufacturing processes using Quintessence’s technology, preparing its cell therapy to advance into clinical trials for the treatment of ischemic stroke. Quintessence Biotech, a developer of cell processing technologies, has completed proof-of-concept testing for its DACS platform with ProtheraCytes®, CellProthera’s proprietary processed CD34+ cells, utilizing a novel approach to cell sorting. The goal of the collaboration is to better preserve the stem cell phenotype, achieve a higher‑quality therapeutic product, and increase cell yields for indications requiring large doses.

"As we prepare to manufacture our ProtheraCytes® for a Phase III trial in patients following acute myocardial infarction, our data suggests the therapeutic approach holds promise following ischemic stroke as well¹. Quintessence Biotech’s technology offers us the potential for higher yield and quality needed for this indication whilst enabling its integration into a streamlined and secure manufacturing process,” said Matthieu de Kalbermatten, CEO of CellProthera. “Despite advances in care, mortality and disability following stroke remain high, a constant reminder that new therapeutic approaches are desperately needed for these patients.”

"Given CellProthera’s clinical success with CD34+ cell-based therapy following post-myocardial infarction, this collaboration will be an important demonstration of our platform’s effectiveness and universality,” said Charles Cavaniol, CEO of Quintessence Biotech. “In leveraging our technology with an experienced leader in the field, we are advancing our goal of making the democratisation and optimisation of cell therapies a tangible reality.”